News

Linnaeus Therapeutics Announces Expanded Clinical Collaboration with Merck to Include Multiple Additional Cohorts to Evaluate LNS8801 in Combination with KEYTRUDA® in Patients with Advanced Cancer Studies Will [...]

Linnaeus Therapeutics Announces Presentation of Positive Phase 1 Clinical Data of LNS8801 at 2021 ASCO Annual Meeting Haddonfield NJ, June 7, 2021--Linnaeus Therapeutics, Inc. (Linnaeus), a privately [...]

Linnaeus Therapeutics Announces Issuance of Composition of Matter Patent for LNS8801 by the U.S. Patent and Trademark Office US Patent 10,934,277 Issued on March 2, 2021 [...]

Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Uveal Melanoma Haddonfield NJ, March 10, 2021--Linnaeus Therapeutics, Inc. (Linnaeus), a privately [...]

Company Commences Phase 2 Study at Multiple Academic Sites in United States Haddonfield NJ, October 13, 2020--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company [...]

Linnaeus announced today announced that it has entered into a clinical collaboration agreement with Merck to evaluate the combination of its lead investigational product candidate LNS8801, and Merck’s anti-PD-1 therapy, KEYTRUDA®(pembrolizumab) in patients with [...]